Article info
Oral Presentations
Progress in biological treatment of RA
OP0100 Overall cancer risk in patients with rheumatoid arthritis treated with tnf inhibitors, tocilizumab, abatacept, or rituximab
Citation
OP0100 Overall cancer risk in patients with rheumatoid arthritis treated with tnf inhibitors, tocilizumab, abatacept, or rituximab
Publication history
- First published June 15, 2017.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions